Seeking Alpha

More on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of...

More on Biogen (BIIB) Q2: net profit +34% to $386.8M, helped by strong sales of multiple-sclerosis treatment Avonex and cancer drug Rituxan, and reflecting a $50M charge last year. Ups FY EPS guidance to $6.20 from $6.15 prior, vs. consensus of 6.22. Shares flat at $139.28, although they had been as high as $142.68. BIIB had gained 27% YTD through yesterday.

Check out Seeking Alpha’s new Earnings Center »

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs